Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival.

BOZEN, SUD-TIROL, Italy, November 2, 2011 /PRNewswire/ -- Health Robotics announced that CytoCare and Japan-based Tosho Inc. recently won a public tender purchasing process,

QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for patients with wild-type KRAS metastatic colorectal cancer (mCRC), following a successful re-examination procedure by Amgen. "This opinion, for which a final European Commission decision is pending, is a welcome step forward and one that may lead to additional treatment options for patients facing an aggressive disease with limited treatment options," said Willard H.

Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.